Global Malaria News
Malaria, which kills more than 400,000 people annually, seems to have far outstripped COVID-19 in sub-Saharan Africa. Monoclonal antibodies could fill gaps left by even highly effective vaccines, but deployment is a challenge largely due to the amount of antibody currently required for infusion. Researchers have created a new best-in-class anti-malarial antibody with an approach that may allow them to create even more protective variants of anti-malarial monoclonal antibodies.
Malaria parasite genomes provide insights and tools for control and elimination in Lake Victoria, Kenya
Scientists are turning to genomics to better understand the epidemiology of malaria and to inform control and elimination interventions and strategies. In the Lake Victoria region of Kenya, malaria burden remains very high despite more than a decade of intense control activities. A team of researchers generated whole Plasmodium falciparum genome sequences from the lake region. Their analyses revealed that malaria parasites from this region appear distinct from other parasites from East Africa, while frequencies of known drug resistance markers were similar to those in other East African parasite populations.
When you have become immune to malaria after having contracted the disease, it seems that the body uses a more efficient protection than if you have been vaccinated against the deadly disease. The researchers believe the new findings may be used to improve existing malaria vaccines.
Malaria, a pathogen transmitted into blood by mosquitoes in tropical climates, is typically thought of as a blood and liver infection. However researchers have detected antibodies primarily made in response to infections in the mucous membranes -- in such areas as the lungs, intestines, or vagina -- in study participants with malaria.
A discovery opens the door to the development of new drugs targeting malaria, one of the deadliest infectious diseases on the planet. The researcher teams performed a screen of soil bacteria extracts for antimalarials and identified an extremely potent inhibitor of malaria development.
Researchers have identified a chemical compound that may be suitable as an active agent against several different unicellular parasites. Among these are the pathogens that cause malaria and toxoplasmosis. The point of attack for this promising substance is the protein tubulin: It helps cells divide and therefore is essential for the multiplication of the parasites.
New research suggests that dengue -- a viral infection spread by mosquitos -- could be suppressed in Singapore in a highly cost-effective manner through the release of mosquitos infected with the bacterium Wolbachia.
Researchers can now detect brand new mutations in individual malaria parasites infecting humans. Such high resolution could help us understand how parasites develop drug resistance and evade immune responses, and suggest potential treatment targets.
Researchers have demonstrated that blood-seeking mosquitoes can be directed to feed on a toxic plant-based solution, which in turn kills them. This result could be one solution for the global problem of diseases like malaria or dengue fever by specifically targeting the mosquitoes while other species like bees won't be affected.
A major tool against malaria in Africa has been the use of rapid diagnostic tests, which have been part of the 'test-treat-track' strategy in Ethiopia, the second most-populated country in Africa. But researchers studying blood samples from more than 12,000 individuals in Ethiopia now estimate these tests missed nearly 10% of malaria cases caused by the parasite Plasmodium falciparum, the most common cause of malaria cases and deaths.
A common antibiotic has been found to reduce low birth weight and premature births, if taken during pregnancy, in countries where malaria is endemic, according to a research review.
A recent study led by an entomologist explores the different kinds of cells that make up mosquito immune systems. The research could shed light on how mosquitoes transmit malaria.
A gene called PfAP2-HS allows the malaria parasite to defend itself from adverse conditions in the host, including febrile temperatures, according to new research. The study resolves a long-standing question on how the parasite responds to changes in its environment.
One dose of a new monoclonal antibody prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people.
Researchers have shown 'gene drive' technology, which spreads a genetic modification blocking female reproduction, works in natural-like settings.
Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.
Infection with dengue virus makes mosquitoes more sensitive to warmer temperatures, according to new research. The team also found that infection with the bacterium Wolbachia, which has recently been used to control viral infections in mosquitoes, also increases the thermal sensitivity of the insects. The findings suggest that global warming could limit the spread of dengue fever but could also limit the effectiveness of Wolbachia as a biological control agent.
The parasites that cause severe malaria are well-known for the sinister ways they infect humans, but new research may lead to drugs that could block one of their most reliable weapons: interference with the immune response.
An estimated 8.4 billion people could be at risk from malaria and dengue by the end of the century if emissions keep rising at current levels, according to a new study.
Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.